Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.
about
Emerging Techniques in Brain Tumor Imaging: What Radiologists Need to KnowPhysiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma.Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas.Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei CountingParametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.Implications of neurovascular uncoupling in functional magnetic resonance imaging (fMRI) of brain tumors.Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.Comparison of intravoxel incoherent motion diffusion-weighted MR imaging with dynamic contrast-enhanced MRI for differentiating lung cancer from benign solitary pulmonary lesions.Association between tumor architecture derived from generalized Q-space MRI and survival in glioblastoma.A mechanically coupled reaction-diffusion model that incorporates intra-tumoural heterogeneity to predict in vivo glioma growth.Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before TherapyA Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies.Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging.Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy.Sodium Fluorescein Facilitates Guided Sampling of Diagnostic Tumor Tissue in Nonenhancing Gliomas.Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer.Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice.Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas.Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study.Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models.
P2860
Q28068259-B4C7BDD7-3B6E-44CC-8EAE-E90F9CC7C35AQ35771783-4CB4FDF6-6CDE-4B9F-9D61-5D5571EF5457Q35849699-D38B0C41-CFCE-4BBB-BE90-4D876AD0AD8AQ35923158-F9B6802E-00BB-414B-958B-99EEAD222536Q36088683-E4BA7EC3-3DBB-4B5B-94FC-3569705EEE33Q36279602-F846750D-9DC6-4506-9FDA-07421B974B7FQ36324977-576C9142-4A07-4719-A97A-A8D4714974C7Q36368541-3D6128F6-1868-4AFD-9AF2-93E4F9FC000CQ36427538-65ADF0B1-5B85-4215-98E0-5BF5DB145AFAQ36785131-8F1FA4F3-5DF3-43AC-BF7B-8C0DE062D72CQ37510450-C6B6F801-9AE2-4432-8B3B-53BB9A228A18Q38580754-BDAA5B15-378D-4E78-83E9-F44EC2F0B4FFQ38839352-DABCBE1B-134B-4205-AA4F-E47660933DF4Q38885308-122C8ADB-336A-4DB0-BC0C-433E0EA4CC7BQ39030177-7B20E63B-29E9-4953-857B-6DA72C1A8BB5Q41529914-006B7605-1E95-4154-9CDD-7173AC0E2E7BQ43653887-6E1D9628-D89D-4459-801E-8CC1003764E9Q47385641-1FDD802C-1084-4FF5-8491-37BF523B3C15Q47827207-3E66FE30-1E72-4648-A693-14852478D626Q48095690-D62DAE6A-4423-4E73-8DD8-0422C52BEF27Q48226825-BC542345-E4A7-4354-91D2-03448D89FFA3Q48245198-2444108D-76C7-4FA0-81B4-BF967C369525Q49344442-F757C422-7B4D-4FDE-A978-F72E156A9645Q51416304-BCBC40CF-5BFC-41F6-84BD-2473B9383B72Q52149108-D46F20D5-4FDD-4791-B44C-46D095A1AD5DQ52582028-3E06D63C-9B2D-464E-975B-A6098716C584Q52891816-81AE41DC-DC47-48E9-9092-3D4BA70CE5F4
P2860
Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@ast
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@en
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@nl
type
label
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@ast
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@en
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@nl
prefLabel
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@ast
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@en
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@nl
P2093
P2860
P356
P1433
P1476
Precise ex vivo histological v ...... 7 cases of high-grade glioma.
@en
P2093
Elizabeth J Cochran
Jennifer Connelly
Joseph A Bovi
Kathleen M Schmainda
Mark G Malkin
Nikolai J Mickevicius
Peter S LaViolette
Scott D Rand
Wade M Mueller
P2860
P304
P356
10.1093/NEUONC/NOU142
P577
2014-07-24T00:00:00Z